AzTrials
AzTrials

HypertensionEBJIPHWNCT06584331

BEETROOT JUICE INTAKE in POSTMENOPAUSAL HYPERTENSIVE WOMEN

A study testing 1 dose of Beetroot juice intake and 2 doses of Beetroot juice intake in people with Hypertension and Menopause, run by Federal University of Uberlandia at 1 site in Brazil.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to verify the hemodynamic and biomarker responses of beetroot juice intake in postmenopausal women with hypertension. The main questions it aims to answer are: Is beetroot juice dose related to better hemodynamic responses in hypertensive postmenopausal women? Is beetroot juice dose… Read more about this study

Who is it for?
Ages 45 to 65 years, women only
Conditions the study is for
Hypertension, Menopause
What is being tested?
1 dose of Beetroot juice intake and 2 doses of Beetroot juice intake
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
48 participants
Where
1 siteBrazil
Study dates
7 Aug 2024to Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Amenorrhea for at least 12 months
  • Controlled hypertension

Who cannot join

  • Decompensated hypertension in stages 2 and 3
  • Having a history of stroke or acute myocardial infarction
  • Smoker
  • Having a diagnosis of Diabetes Mellitus
  • Using hormone therapy.

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • FAEFI

    Uberlândia, Minas Gerais, 38400-678

Other trials in Brazil

About this study

Official title: HEMODYNAMIC and BIOCHEMICAL RESPONSES to 10 DAYS of BEETROOT JUICE INTAKE in POSTMENOPAUSAL HYPERTENSIVE WOMEN

The goal of this clinical trial is to verify the hemodynamic and biomarker responses of beetroot juice intake in postmenopausal women with hypertension. The main questions it aims to answer are:

Is beetroot juice dose related to better hemodynamic responses in hypertensive postmenopausal women? Is beetroot juice dose related to better oxidative stress profile responses in hypertensive postmenopausal women?

The investigators will conduct a parallel clinical study with 10 days of intervention, in which 48 women will be randomized into 3 groups: 1) Two shots of beetroot juice intake per day (800mg of NO3-); 2) One shot of beetroot juice intake per day (400mg of NO3-); 3) placebo intake (beetroot juice without NO3-).

Read the detailed description

The entire intervention will take place at the Physical Education campus of University, in the Cardiorespiratory and Metabolic Physiology Laboratory (LAFICAM). The recruitment and approach of the volunteers will occur through media dissemination, such as radio announcements, television programs, and social media through digital media. After the dissemination, volunteers will make contact via phone, email, or social media, and a preliminary registration will take place. After this registration, the researchers will verify which volunteers meet the inclusion criteria, and only then will the recruitment take place.

The volunteers will be invited to come to LAFICAM to be informed about the intervention program and then sign the informed consent form. Before starting the intervention program, all volunteers must present a medical certificate clearing them to participate in a physical exercise training program; once the certificate is submitted, initial tests and general evaluations will be conducted.

The initial evaluations will consist of a questionnaire, anthropometric and body composition assessment, and evaluation of the physical activity level. After the questionnaires are administered, a familiarization with the sensory perceptions of beetroot juice will be conducted. This familiarization is important to verify if the volunteers are fit to carry out the intervention.

The volunteers will be randomized into three groups: Group 1: the volunteers will ingest two shots containing 70 ml of beetroot juice with 400 mg of nitrate per day, one shot in the mornig and one shot at night, for 10 days; Group 2: this group will intake 70 ml of beetroot juice with 400 mg of nitrate every morning.

Group 3: this group will intake 70 ml of beetroot juice without nitrate for 10 days.

Being tested
1 dose of Beetroot juice intake, 2 doses of Beetroot juice intake, Placebo
Keywords
beetroot juice, hypertension, postmenopausal, blood pressure
Medical subject headings
Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1 dose of Beetroot juice intakeDietary supplement

    The volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days

  • 2 doses of Beetroot juice intakeDietary supplement

    This group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.

  • PlaceboDietary supplement

    In this group, the participants will receive 70ml of low-nitrate beetroot juice to consume in the morning.

Study groups in NCT06584331
Study groupRoleWhat they receive
1 dose of beetroot juiceExperimentalThe volunteers will ingest 70 ml of beetroot juice with 400 mg of nitrate every morning for 10 days
Receives: Dietary Supplement: 1 dose of Beetroot juice intake
2 doses of beetroot juiceExperimentalThis group will ingest 2 shots of 70 ml of beetroot juice with 400mg of nitrate, in each shot, for 10 days.
Receives: Dietary Supplement: 2 doses of Beetroot juice intake
PlaceboPlacebo comparatorIn this group, the participants will receive a low-nitrate beetroot juice dose to consume in the morning.
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood Pressure

    Volunteers will undergo blood pressure tests at the beginning, in the middle and after the 10 days of intervention. To assess blood pressure (BP), researchers will use the Dyna Mapa + Cardius® device, programmed with measurements to be taken every 20 min. Together with this device, the volunteers filled out a daily record of activities such as sleep, work, food, or any event that could interfere with BP or measurements. In a standardized manner, the device was set at 7 a.m., and measurements were considered valid when 24h of monitoring were obtained. Resting BP was measured with the same device after 15 min of rest in a sitting position, and for the analysis of the pressure curve, time 0 was adopted when the monitor was placed. Sytolic BP, diastolic BP, and mean BP in periods of awake, sleep and 24 h were analyzed.

    Measured: 11 days

Secondary outcomes (8)
  1. Stroop color and word test

    The evaluation of the blood pressure (BP) reactivity was carried out under mental stress, through the electronic version of Stroop protocol (3 minutes). For the test, the volunteers sited in front of a computer screen with a headset and listened to a voice speaking names of different colors and with images changing every 2 seconds. Each image consisted of a word forming the name of a color, with the word's letters color being different from the color's name, and with the bottom of the word with another color different from the color of the word and the color's name formed by the word. The volunteers should speak as quickly as possible the name of the color formed by the letters in the image. Before the test, baseline BP were measure once after resting in siting position during 15 minutes. During the test, the volunteers BP was measured every minute, through the auscultatory method.

    Measured: 11 days

  2. Heart rate variability

    Resting R-R intervals will be recorded for 15 min in the seated position using an HR monitor (POLAR® RS800cx; Polar Electro Oy, Finland; sampling frequency = 1000 Hz) with spontaneous breathing. Data will be downloaded to a computer using an infrared interface with specific software (POLAR PRO TRAINER5®, Polar Electro, Kempele, Finland). Heart rate variability (HRV) analysis was performed using KUBIOS HRV 3.0. Prior to the analysis, the signal will be visually inspected and filtered, and a range of 5 min interval with few artifacts will be selected near the end of the recording for analysis. The resulting R-R intervals will be analyzed in the time domain, in the frequency domain using spectral analysis (Fast Fourier Transform), and non-linearly through the Poincaré diagram.

    Measured: 11 days

  3. Superoxide Dismutase

    Superoxide Dismutase (SOD) activity will be assessed by inhibition of pyrogallol autoxidation. Samples will be mixed with 50 mmol L Tris-HCl buffer (pH 8.2) containing 1 mmol L EDTA to deactivate metal-dependent enzymes, 80 U mL 1 catalase, and 24 mmol L 1 pyrogallol, and the kinetic assay will be monitored for 10 min at 420 nm using an analytical curve constructed with SOD as a standard.

    Measured: 11 days

  4. Catalase

    Catalase (CAT) activity will be based on the decomposition of hydrogen peroxide. Samples will be mixed with a 10 mmol_L^-1 potassium phosphate buffer (pH 7.0 containing 0.2% hydrogen peroxide. Hydrogen peroxide decomposition will be monitored at 240 nm for 10 min.

    Measured: 11 days

  5. Glutathione Peroxidase

    To measure glutathione peroxidase (GPx) activity, plasma will be incubated with GPx buffer (100 mM potassium phosphate containing 1 mM EDTA, pH 7.7), sodium azide (40 mM), glutathione (GSH) (diluted in 5% metaphosphoric acid), glutathione reductase (GR) (diluted in GPx buffer), NADPH (diluted with 5% sodium bicarbonate), and tert-butyl hydroperoxide (0.5 mM). The reduction in NADPH concentration will be assessed for 10 min in a spectrophotometer at 340 nm.

    Measured: 11 days

  6. Total antioxidant capacity due to ferric-reducing antioxidant power (FRAP)

    The total antioxidant capacity due to iron reducing antioxidant power (FRAP) will be determined by the ability of the antioxidants present in the blood samples to reduce Fe3+ to Fe2+, which is chelated by TPTZ (2,4,6-tris(2-pyridyl)-s-triazine) and forms the Fe2+ TPTZ complex. This complex will be quantified in a spectrophotometer at 593 nm, and the antioxidant activity will be determined by means of an analytical curve, constructed with trolox as a standard.

    Measured: 11 days

  7. Reduced glutathione (GSH)

    Plasma proteins will be precipitated with metaphosphoric acid (MPA) and centrifuged at 7000 g for 10 min. The supernatant will be collected and mixed with 100 mM sodium phosphate buffer (pH 8.0) containing 5 mM EDTA and 15 μL ortho-phthaldialdehyde (1 mg/mL in methanol, HPLC grade, 99.9%). The solution will be incubated in the dark at room temperature for 15 min. Fluorescence will be read at 350 nm (excitation) and 420 nm (emission). Glutathione (GSH) concentrations of the sample will be calculated using a GSH standard curve (0.001-0.1 mM)

    Measured: 11 days

  8. Human cytokines

    Human cytokines (IL-8, IL-1β, IL-6, TNF, IL-10 and IL-12p70) in serum samples will be measured by flow cytometry technique (FACSCantoII BD™, San Jose, CA, USA) using a human inflammatory cytokine kit (BD™ Cytometric Bead Array (CBA), BD Biosciences, San Jose, CA, USA) according to the manufacturer\'s instructions.

    Measured: 11 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Sep 2024
  2. Study start7 Aug 2024
  3. Primary completionJul 2025 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
48 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06584331
Sponsor's protocol ID
01.78649524.4.0000.5152
Other IDs
APQ-01874-18, 175522/2023-5
Acronym
EBJIPHW
Status last verified
Aug 2024
First submitted
26 Aug 2024
Last updated
23 Sep 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The IPD will not be made available, but it can be sent by email upon request.

Questions about this trial

What is this clinical trial studying?

A study testing 1 dose of Beetroot juice intake and 2 doses of Beetroot juice intake in people with Hypertension and Menopause, run by Federal University of Uberlandia at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 23 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood Pressure (time frame: 11 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in